These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 6221496

  • 21. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method.
    Soufir JC, Meduri G, Ziyyat A.
    Hum Reprod; 2011 Jul; 26(7):1708-14. PubMed ID: 21551452
    [Abstract] [Full Text] [Related]

  • 22. The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels.
    Frick J, Bartsch G, Weiske WH.
    Contraception; 1977 Jun; 15(6):649-68. PubMed ID: 891192
    [Abstract] [Full Text] [Related]

  • 23. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR, Kletzky OA, Brenner PF, Roy S, Nicoloff J.
    Am J Obstet Gynecol; 1977 May 01; 128(1):60-74. PubMed ID: 403765
    [Abstract] [Full Text] [Related]

  • 24. Relationship between hormone profiles and the restoration of spermatogenesis in men treated with gossypol.
    Gu ZP, Wang YX, Sang GW, Wang WC, Chen ZX, Zhao XJ, Shao QX, Jiang Y.
    Int J Androl; 1990 Aug 01; 13(4):253-7. PubMed ID: 2117586
    [Abstract] [Full Text] [Related]

  • 25. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug 01; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 26. Endocrinological and physiological features after steroid treatment of male rats.
    Hunt DM, Lau IF, Saksena SK, Chang MC.
    Arch Androl; 1978 Sep 01; 1(4):311-20. PubMed ID: 736678
    [Abstract] [Full Text] [Related]

  • 27. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM.
    J Clin Endocrinol Metab; 1991 Dec 01; 73(6):1360-9. PubMed ID: 1955518
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
    Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E.
    Contraception; 1984 Jan 01; 29(1):1-18. PubMed ID: 6234145
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Endocrine, seminal and peripheral effects of depot medroxyprogesterone acetate and testosterone enanthate in men.
    Hedman M, Gottlieb C, Svanborg K, Bygdeman M, de la Torre B.
    Int J Androl; 1988 Aug 01; 11(4):265-76. PubMed ID: 2971625
    [Abstract] [Full Text] [Related]

  • 34. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS.
    J Clin Endocrinol Metab; 1992 Aug 01; 75(2):476-83. PubMed ID: 1639948
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM, Nashan D, Hubert W, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Jan 01; 74(1):84-90. PubMed ID: 1727833
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The effect of levonorgestrel and estrone rods on male reproductive function.
    Brache V, Alvarez-Sánchez F, León P, Schmidt F, Faundes A.
    Contraception; 1982 Jun 01; 25(6):591-603. PubMed ID: 6811196
    [Abstract] [Full Text] [Related]

  • 39. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA, Brenner PF, Kletzky OA, Mishell DR.
    Am J Obstet Gynecol; 1978 Apr 01; 130(7):817-21. PubMed ID: 345817
    [Abstract] [Full Text] [Related]

  • 40. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
    McLachlan RI, O'Donnell L, Stanton PG, Balourdos G, Frydenberg M, de Kretser DM, Robertson DM.
    J Clin Endocrinol Metab; 2002 Feb 01; 87(2):546-56. PubMed ID: 11836283
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.